In vivo serotonin-sensitive binding of [11C]CUMI-101: A serotonin 1A receptor agonist positron emission tomography radiotracer

Journal of Cerebral Blood Flow and Metabolism

Volumn 31, Issue 1, 2011, Pages 243-249

  Milak, Matthew S ^a,b   Severance, Alin J ^a   Prabhakaran, Jaya ^a   Kumar, J S Dileep ^a,b   Majo, Vattoly J ^a   Ogden, R Todd ^a,b   Mann, J John ^a,b   Parsey, Ramin V ^a,b  

^a College of Physicians and Surgeons ^*  (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

graphical approach; in vivo; kinetic modeling; Lassen plot; positron emission tomography; VT fp

Indexed keywords

CARBON 11; CITALOPRAM; CUMI 101; CUMI 101 C 11; FENFLURAMINE; G PROTEIN COUPLED RECEPTOR; SEROTONIN; SEROTONIN 1A AGONIST; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG CLEARANCE; DRUG RECEPTOR BINDING; DRUG SENSITIVITY; IMAGE ANALYSIS; IMAGE PROCESSING; MALE; NEUROIMAGING; NONHUMAN; PAPIO ANUBIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN CONFORMATION; RECEPTOR OCCUPANCY; RECEPTOR SENSITIVITY; SYNAPTIC TRANSMISSION;

ANIMALS; BINDING, COMPETITIVE; CITALOPRAM; FENFLURAMINE; IMAGE PROCESSING, COMPUTER-ASSISTED; INJECTIONS, INTRAVENOUS; MALE; PAPIO ANUBIS; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SYNAPSES; TRIAZINES;

EID: 78650896327     PISSN: 0271678X     EISSN: None     Source Type: Journal    
DOI: 10.1038/jcbfm.2010.83     Document Type: Article

References (42)

1. Abi-Dargham A, Laruelle M, Aghajanian GK, Charney D, Krystal J (1997) The role of serotonin in the pathophysiology and treatment of schizophrenia. J Neuropsychiatry Clin Neurosci 9:1-17
2. Cheney BV, Lahti RA, Barsuhn C, Gay DD (1982) An analysis of binding at the opioid receptor based upon an agonist/antagonist two-state model. Mol Pharmacol 22:349-59
3. Cumming P, Wong DF, Gillings N, Hilton J, Scheffel U, Gjedde A (2002) Specific binding of [(11)C]raclopride and N-[(3)H]propyl-norapomorphine to dopamine receptors in living mouse striatum: occupancy by endogenous dopamine and guanosine triphosphate-free G protein. J Cereb Blood Flow Metab 22:596-604
4. Cunningham VJ, Rabiner EA, Slifstein M, Laruelle M, Gunn RN (2010) Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited. J Cereb Blood Flow Metab 30:46-50
5. Cunningham VJ, Gunn RN, Matthews JC (2004) Quantification in positron emission tomography for research in pharmacology and drug development. Nucl Med Commun 25:643-6
6. Frankle WG, Lombardo I, Kegeles LS, Slifstein M, Martin JH, Huang Y, Hwang DR, Reich E, Cangiano C, Gil R, Laruelle M, Abi-Dargham A (2006) Serotonin 1A receptor availability in patients with schizophrenia and schizo-affective disorder: a positron emission tomography imaging study with [11C]WAY 100635. Psychopharmacology (Berl) 189:155-64
7. Fredricson Overo K (1982) Kinetics of citalopram in man; plasma levels in patients. Prog Neuropsychopharmacol Biol Psychiatry 6:311-8
8. Gandelman MS, Baldwin RM, Zoghbi SS, Zea-Ponce Y, Innis RB (1994) Evaluation of ultrafiltration for the freefraction determination of single photon emission computed tomography (SPECT) radiotracers: beta-CIT, IBF, and iomazenil. J Pharm Sci 83:1014-9
9. Ginovart N, Wilson AA, Meyer JH, Hussey D, Houle S (2001) Positron emission tomography quantification of [(11)C]-DASB binding to the human serotonin transporter: modeling strategies. J Cereb Blood Flow Metab 21:1342-53
10. Hjorth S (1993) Serotonin 5-HT1A autoreceptor blockade potentiates the ability of the 5-HT reuptake inhibitor citalopram to increase nerve terminal output of 5-HT in vivo: a microdialysis study. J Neurochem 60:776-9
11. Hoebel BG, Hernandez L, Schwartz DH, Mark GP, Hunter GA (1989) Microdialysis studies of brain norepinephrine, serotonin, and dopamine release during ingestive behavior. Theoretical and clinical implications. Ann N Y Acad Sci 575:171-91; discussion 92-3
12. Hume S, Hirani E, Opacka-Juffry J, Myers R, Townsend C, Pike V, Grasby P (2001a) Effect of 5-HT on binding of [(11)C] WAY 100635 to 5-HT(IA) receptors in rat brain, assessed using in vivo microdialysis nd PET after fenfluramine. Synapse (New York, NY) 41:150-9
13. Hume S, Hirani E, Opacka-Juffry J, Myers R, Townsend C, Pike V, Grasby P (2001b) Effect of 5-HT on binding of [11C]WAY 100635 i 5-HT1A receptors in rat brain, assessed using in vivo microdialysis and PET after fenfluramine. Synapse 41:150-9
14. Judd FK, Apostolopoulos M, Burrows GD, Norman TR (1994) Serotonergic function in panic disorder: endocrine responses to D-fenfluramine. Prog Neuropsychopharmacol Biol Psychiatry 18:329-37
15. Kumar JS, Mann JJ (2007) PET tracers for 5-HT(1A) receptors and uses thereof. Drug Discov Today 12: 748-56
16. Kumar JS, Prabhakaran J, Majo VJ, Milak MS, Hsiung SC, Tamir H, Simpson NR, Van Heertum RL, Mann JJ, Parsey RV (2007) Synthesis and in vivo evaluation of a novel 5-HT(1A) receptor agonist radioligand [O-methyl-(11)C]2-(4-(4-(2- methoxyphenyl)piperazin-1-yl)butyl)-4-methyl-1,2,4-triazi ne-3,5(2H,4H)dione in nonhuman primates. Eur J Nucl Med Mol Imaging 34:1050-60
17. Laferrere B, Wurtman RJ (1989) Effect of D-fenfluramine on serotonin release in brains of anaesthetized rats. Brain Res 504:258-63
18. Lahti RA, Figur LM, Piercey MF, Ruppel PL, Evans DL (1992) Intrinsic activity determinations at the dopamine D2 guanine nucleotide-binding protein-coupled receptor: utilization of receptor state binding affinities. Mol Pharmacol 42:432-8
19. Lassen NA, Bartenstein PA, Lammertsma AA, Prevett MC, Turton DR, Luthra SK, Osman S, Bloomfield PM, Jones T, Patsalos PN, Oconnell MT, Duncan JS, Andersen JV (1995) Benzodiazepine receptor quantification in vivo in humans using [11C]flumazenil and PET: application of the steady-state principle. J Cereb Blood Flow Metab 15:152-65
20. Maeda J, Suhara T, Ogawa M, Okauchi T, Kawabe K, Zhang MR, Semba J, Suzuki K (2001) In vivo binding properties of [carbonyl-11C]WAY-100635: effect of endogenous serotonin. Synapse 40:122-9
21. Mathis C, Simpson N, Price J, Mahmood K, Bowman K, Mintun M (1995) Evaluation of [11C1]WAY 100635: a potent serotonin 5-HT1A receptor antagonist. J Nucl Med 36:162
22. Abstract Mawlawi O, Martinez D, Slifstein M, Broft A, Chatterjee R, Hwang DR, Huang Y, Simpson N, Ngo K, Van Heertum R, Laruelle M (2001) Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D(2) receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab 21:1034-57
23. Milak MS, Ogden RT, Vinocur DN, Van Heertum RL, Cooper TB, Mann JJ, Parsey RV (2005) Effects of tryptophan depletion on the binding of [(11)C]-DASB to the serotonin transporter in baboons: response to acute serotonin deficiency. Biol Psychiatry 57:102-6
24. Milak MS, Severance AJ, Ogden RT, Prabhakaran J, Kumar JS, Majo VJ, Mann JJ, Parsey RV (2008) Modeling considerations for 11C-CUMI-101, an agonist radiotracer for imaging serotonin 1A receptor in vivo with PET. J Nucl Med 49:587-96
25. Narendran R, Hwang DR, Slifstein M, Talbot PS, Erritzoe D, Huang Y, Cooper TB, Martinez D, Kegeles LS, Abi-Dargham A, Laruelle M (2004) In vivo vulnerability to competition by endogenous dopamine: comparison of the D2 receptor agonist radiotracer (-)-N-[11C]propylnorapomorphine ([11C]NPA) with the D2 receptor antagonist radiotracer [11C]-raclopride. Synapse 52:188-208
26. Ogden RT (2003) Estimation of kinetic parameters in graphical analysis of PET imaging data. Stat Med 22: 3557-68
27. Parsey RV, Hwang DR, Simpson N, Kegeles L, Anjivel S, Zea-Ponce Y, Lombardo I, Popilskis S, Van Heertum R, Mann JJ, Laruelle M (1998) Kinetic derivation of serotonin 5-HT-1A receptor binding potential with [C-11]carbonyl-WAY 100635 and competition studies with endogenous serotonin. J Nucl Med 39:167P
28. Parsey RV, Hwang DR, Simpson N, Guo NN, Mawlawi O, Kegeles LS, Bergert B, Montoya J, Popilskis S, Mann JJ, Laruelle M (1999) PET studies of competition between [C-11]carbonyl-way 100635 and endogenous serotonin. J Nucl Med 40:29P
29. Parsey RV, Ogden RT, Mann JJ (2003) Determination of volume of distribution using likelihood estimation in graphical analysis: elimination of estimation bias. J Cereb Blood Flow Metab 23:1471-8
30. Parsey RV, Arango V, Olvet DM, Oquendo MA, Van Heertum RL, John Mann J (2005) Regional heterogeneity of 5-HT1A receptors in human cerebellum as assessed by positron emission tomography. J Cereb Blood Flow Metab 25:785-93
31. Parsey RV, Oquendo MA, Ogden RT, Olvet DM, Simpson N, Huang YY, Van Heertum RL, Arango V, Mann JJ (2006) Altered serotonin 1A binding in major depression: a [carbonyl-C-11]WAY100635 positron emission tomography study. Biol Psychiatry 59:106-13
32. PDSP Database-UNC %U (2010) http://kidb.cwru.edu/ pdsp.php
33. Rabiner EA, Messa C, Sargent PA, Husted-Kjaer K, Montgomery A, Lawrence AD, Bench CJ, Gunn RN, Cowen P, Grasby PM (2002) A database of [(11)C]WAY-100635 binding to 5-HT(1A) receptors in normal male volunteers: normative data and relationship to methodological, demographic, physiological, and behavioral variables. Neuroimage 15:620-32
34. Sharp T, Bramwell SR, Clark D, Grahame-Smith DG (1989) In vivo measurement of extracellular 5-hydroxytryptamine in hippocampus of the anaesthetized rat using microdialysis: changes in relation to 5-hydroxytryptaminergic neuronal activity. J Neurochem 53:234-40
35. Theodore WH, Hasler G, Giovacchini G, Kelley K, Reeves-Tyer P, Herscovitch P, Drevets W (2007) Reduced hippocampal 5HT1A PET receptor binding and depression in temporal lobe epilepsy. Epilepsia 48:1526-30
36. Udo de Haes JI, Bosker FJ, Van Waarde A, Pruim J, Willemsen AT, Vaalburg W, Den Boer JA (2002) 5-HT(1A) receptor imaging in the human brain: effect of tryptophan depletion and infusion on [(18)F]MPPF binding. Synapse 46:108-15
37. Udo de Haes JI, Cremers TI, Bosker FJ, Postema F, Tiemersma-Wegman TD, den Boer JA (2005) Effect of increased serotonin levels on [18F]MPPF binding in rat brain: fenfluramine vs the combination of citalopram and ketanserin. Neuropsychopharmacology 30:1624-31
38. Udo de Haes JI, Harada N, Elsinga PH, Maguire RP, Tsukada H (2006) Effect of fenfluramine-induced increases in serotonin release on [18F]MPPF binding: a continuous infusion PET study in conscious monkeys. Synapse (New York, NY) 59:18-26
39. Watson C, Newport D, Casey M (1996) A single scatter simulation technique for scatter correction in 3D PET. In: Three-dimensional image reconstruction in radiology and nuclear medicine (Grangeat P, Amans J-L, eds), Dordrecht; Boston: Kluwer Academic Publishers, pp 255-68 ISBN: 0792341295
40. Whittington RA, Virag L (2006) Isoflurane decreases extracellular serotonin in the mouse hippocampus. Anesth Analg 103:92-8, table of contents
41. Wu S, Ogden RT, Mann JJ, Parsey RV (2007) Optimal metabolite curve fitting for kinetic modeling of 11CWAY-100635. J Nucl Med 48:926-31
42. Zimmer L, Mauger G, Le Bars D, Bonmarchand G, Luxen A, Pujol JF (2002) Effect of endogenous serotonin on the binding of the 5-hT1A PET ligand 18F-MPPF in the rat hippocampus: kinetic beta measurements combined with microdialysis. J Neurochem 80:278-86